NCT05198388

Brief Summary

Measurement of Beta endorphins,interleukin 1 and interleukin 38 in covid patients associated with neuropsychological manifestations.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 19, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 20, 2022

Completed
1.1 years until next milestone

Study Start

First participant enrolled

March 1, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2024

Completed
Last Updated

January 25, 2022

Status Verified

January 1, 2022

Enrollment Period

1.1 years

First QC Date

January 19, 2022

Last Update Submit

January 22, 2022

Conditions

Covid Patients

Outcome Measures

Primary Outcomes (1)

  • - Detection of βeta endorphins, interleukin 6 and interleukin 38 in serum of COVID-19 patients.

    \- Detection of βeta endorphins, interleukin 6 and interleukin 38 in serum of COVID-19 patients.

    3 years

Interventions

βeta endorphins, interleukin 6 and interleukin 38DIAGNOSTIC_TEST

* \- Collection of peripheral blood samples in gel tube. * \- Creparation of samples in centrifuge to obtain serum. * \- Measurement of interleukin 6 and interleukin 38 and βeta endorphins using ELISA method.

Eligibility Criteria

Age2 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Sixity patients diagnosed with Covid-19 (30 patients with neurological manifestations and 30 patients without neurological manifestations) 30 healthy individuals as control group with matched age and sex.

You may not qualify if:

  • Other respiratory diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university

Asyut, Egypt

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum sample

Central Study Contacts

somaya redwan younes, master

CONTACT

01099865482somayaredwanmalak@gmail.com

Eman mosaad zaki, doctor

CONTACT

01065518821Eman_mosaad@hotmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer

Study Record Dates

First Submitted

January 19, 2022

First Posted

January 20, 2022

Study Start

March 1, 2023

Primary Completion

March 30, 2024

Study Completion

March 30, 2024

Last Updated

January 25, 2022

Record last verified: 2022-01

Locations

EG(1)